ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 94 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.15 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $506,085 | +51753.0% | 95,308 | -6.9% | 0.03% | -44.8% |
| Q2 2023 | $976 | -35.1% | 102,413 | -25.1% | 0.06% | -37.0% |
| Q1 2023 | $1,505 | -23.4% | 136,804 | +3.0% | 0.09% | -24.0% |
| Q4 2022 | $1,965 | -99.9% | 132,772 | +47.1% | 0.12% | +7.1% |
| Q3 2022 | $1,725,000 | -12.6% | 90,264 | -2.6% | 0.11% | -7.4% |
| Q2 2022 | $1,974,000 | +17.3% | 92,653 | +6.0% | 0.12% | +37.1% |
| Q1 2022 | $1,683,000 | +24.2% | 87,369 | +33.7% | 0.09% | +32.8% |
| Q4 2021 | $1,355,000 | +85.4% | 65,348 | +113.6% | 0.07% | +76.3% |
| Q3 2021 | $731,000 | +33.2% | 30,596 | +52.1% | 0.04% | +31.0% |
| Q2 2021 | $549,000 | – | 20,119 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |